Patient experience in a diabetic program project improves subsequent pregnancy outcome

There has been a notable improvement in the outcome of the pregnancies of insulin-dependent diabetics. This improvement has resulted from intensive health care programs and increased awareness among patients and health providers of the need for specialized prenatal care. We hypothesized that participation in a specialized program providing early glycemic control would benefit the patient's subsequent pregnancy, despite progression of the diabetic disease process. We prospectively studied 55 insulin-dependent diabetic patients enrolled before 9 weeks' gestation through two consecutive pregnancies: sequence 1 and sequence 2. A control group of 55 insulin-dependent diabetic patients, entering the program for the first time, were matched with the sequence 2 pregnancies of the study group by maternal age and year of pregnancy. Specific outcomes related to glycemic control in early gestation were significantly improved from sequence 1 to sequence 2 pregnancies: earlier week of entry (P = .0001), lower glycohemoglobin at 9 weeks (P = .005) and at 14 weeks (P = .02), and improved fetal outcome (decreased rate of spontaneous abortions or major malformations; P less than .01). Week of entry and glycohemoglobin at 9 and 14 weeks were also significantly improved compared with the control group. Seventy-three percent of the patients entered the program earlier in their sequence 2 pregnancies (P = .001) and had lower glycohemoglobin concentrations at 9 weeks (P = .005) compared with their sequence 1 pregnancies. Sixty-five percent of the patients in sequence 2 had advanced diabetic disease (White class D-RF), compared with 46% in sequence 1 (P less than .05) and 44% of the controls (P less than .05).(ABSTRACT TRUNCATED AT 250 WORDS)     

Amniotic Fluid β2 Microglobulin: Correlation with L/S Ratios and Creatinine Levels

Beta 2 microglobulin (beta 2 m) levels were measured in amniotic fluids taken after the 32nd week of gestation. Beta 2 m levels fell continuously from 5.2 microgram/ml at the 32nd week to 3.08 microgram/ml after the 39th week of gestation. Abnormally high levels of beta 2 m were found in 12.6% of samples. There was a significant correlation between beta 2 m levels and lecithin/sphingomyelin ratios at 32 weeks of gestation and with creatinine levels at 37-38 weeks (P less than .05). Although elevated beta 2 m levels may be associated with maternal and/or fetal abnormalities, the precise relationship is not clearly established: in particular, our data do not suggest that estimation of beta 2 m levels could be of value in determining fetal maturity.     

A randomized study of fetal abdominal diameter and fetal weight estimation for detection of light-for-gestation infants in low-risk pregnancies

Summary. A total of 2771 pregnant women with gestational age esti-mated by ultrasound measurement of the fetal biparietal diameter (BPD) before the 22nd week of gestation were re-examined by ultrasound in the 32nd and 37th week of pregnancy at which time the fetal BPD and abdominal diameter (AD) were measured. An additional examination was performed at 34 weeks if the fetal weight in the 32nd week was estimated to be less than 95% of the expected mean weight. Light-for-gestational age (LGA) was suspected if the estimated birth-weight was less than 85% of the expected mean birthweight. This applied to 186 uncomplicated pregnancies in which there was no clinical suspicion of poor intrauterine growth. These pregnancies were randomly allocated to a treatment group (AD and estimated weight reported) or to a control group (AD and estimated weight withheld). Induction of labour was significantly more common in the treatment group (41%) than in the control group (15%). No statistically significant difference was found in the use of instrumental vaginal delivery or caesarean section. There was a Suggestion of marginal benefit in terms of neonatal morbidity but this was not statistically significant.     

Fetal anterior abdominal wall thickness in diabetic pregnancy

OBJECTIVE: The purpose of this study was to investigate whether third trimester fetal anterior abdominal wall (AAW) thickness in diabetic pregnancy reflects glycaemic control and predicts macrosomia. STUDY DESIGN: Prospective cohort study in a tertiary level maternity unit. One hundred and twenty-five diabetic mothers (71 pre-gestational and 54 gestational diabetics on insulin) underwent routine serial third trimester ultrasound examination with the additional measurement of AAW thickness. Pregnancy outcome was obtained. RESULTS: 335 fetal AAW measurements were recorded in diabetic pregnancy from 30 to 38 weeks gestation. Third trimester AAW was significantly higher in macrosomic babies (5.4+/-1.4mm vs. 4.7+/-1.4mm, p<0.05). ROC derived cut off for AAW in the prediction of macrosomia was 3.5mm at 30 weeks, 4.5mm at 33 weeks and 5.5mm at 36 weeks gestation. Using either a raised AAW measurement or an AC>90th centile, the prediction of birth weight greater than the 90th centile was better (88%) than with AC alone (70%). This improvement in sensitivity held even at earlier gestations in the third trimester. CONCLUSION: Measurement of AAW in diabetic pregnancy may have a role in the prediction of macrosomia.     

Early prediction of fetal macrosomia in diabetes mellitus

We studied 374 pregnant diabetic women to determine the value of various ultrasound parameters in the prediction of fetal macrosomia. The correlation between ultrasonographic signs and maternal glycaemia in the development of fetal macrosomia was also studied. Significant correlation was observed between the accurence of hydramnios and future macrosomia during the second-trimester (p less than 0.001). Serum fructosamine levels as an index of maternal glycaemia in patients of macrosomic fetuses were significantly higher throughout the pregnancy as compared with mothers of infants with normal birth weight (p less than 0.001). These data suggest: 1. The presence of hydramnios in the second trimester is a useful predictor of macrosomia in diabetic patients (specificity: 86%, negative predictive value: 88%). 2. Maternal diabetic control during pregnancy has a significant influence on fetal growth and contributes to the development of fetal macrosomia. 3. The lack of correlation between the frequency of hydramnios and fructosamine levels suggests that a mechanism other than carbohydrate metabolism also plays an important role in the development of fetal macrosomia.     

Glycosylated hemoglobin concentration in early gestation associated with neonatal outcome

Previous studies have indicated an association of fetal macrosomia with mild degrees of glucose intolerance in late pregnancy. To determine whether glycosylated hemoglobin concentration in early gestation was related to fetal outcome, 48 pregnant women with normal glucose tolerance and 21 women with gestational diabetes were studied. Glycosylated hemoglobin concentration was determined by a specific aminophenylboronic acid assay, and mean glycosylated hemoglobin concentration was calculated from two or three determinations before 17 weeks' gestation. The incidence of infants large for gestational age was 10% in nondiabetic women with glycosylated hemoglobin concentration of less than 6.0%. With glycosylated hemoglobin concentration of 6.0% to 6.9%, the incidence of infants who were large for gestational age was increased in both nondiabetic women (75%, p less than 0.01) and diabetic women (40%, p less than 0.01). With glycosylated hemoglobin concentration of greater than 7.0%, 36% of infants of diabetic women were large for gestational age. The incidence of hyperbilirubinemia was 2.5% in the infants of nondiabetic women with glycosylated hemoglobin concentration of 6.0%. With glycosylated hemoglobin concentration of 6.0% to 6.9%, hyperbilirubinemia was increased in both the infants of nondiabetic women (38%, p less than 0.01) and diabetic women (30%, p less than 0.01). With glycosylated hemoglobin concentration of greater than 7.0%, hyperbilirubinemia was present in 27% of infants of diabetic mothers. The current study suggests that glycosylated hemoglobin concentration elevation in early gestation is associated with perinatal morbidity.     

Ovarian tumors complicating pregnancy. Emergency and elective surgery

OBJECTIVE: To retrospectively evaluate the different effects and characteristics of ovarian surgery performed under emergency conditions and electively during pregnancy and to search for risk factors contributing to emergency ovarian surgery. STUDY DESIGN: Between 1980 and 1996, 174 patients undergoing adnexal surgery during pregnancy or the puerperium were reviewed at Veterans General Hospital-Taipei. Of these 174 patients, 32 underwent emergency surgery (group A), while 142 patients underwent elective surgery (group B). In order to search for differences between the emergency and elective operations, patients in both groups were analyzed, with particular emphasis on the characteristics and outcome of pregnancy. RESULTS: In contrast to elective operations, there were five distinct aspects of emergency surgery. First, half of them occurred in the first trimester. Second, they contributed to 75% (9/12) of the total fetal wastage and 85.7% (6/7) of spontaneous fetal loss (P = .00016). Third, tumor sizes (11.1 +/- 4.2 cm) were significantly larger than those found (8.3 +/- 3.76 cm) in the elective surgery group (P < .05). Fourth, tumors less than 5 cm never caused symptoms requiring surgery. Fifth, an increasing incidence of completely extirpative surgery and general anesthesia was noted (P < .005). Incidence of tumors greater than 10 cm during pregnancy increased with malignancy (P = .0295) and before emergency surgery (P = .00001). CONCLUSION: We could remove ovarian tumors greater than 10 cm in diameter or with a teratoma component at earlier stages of pregnancy (after the seventh week of gestation) to avoid unpredictable complications. This reduces the risks of malignancy and emergency surgery. There was no evidence of increasing risk of fetal loss when surgery was performed after the seventh week of gestation.     

妊娠期糖尿病患者孕期及产后血清VEGF、sFlt1水平的变化及意义

目的探讨妊娠期糖尿病(GDM)患者孕期及产后血清血管内皮生长因子(VEGF)及其可溶性受体1(sFlt-1)水平的变化及意义。方法对100例GDM患者(其中,FGR21例、巨大儿27例、胎儿正常52例)及30例正常孕妇(对照组),用ELISA法检测各孕妇孕28周、32周、36周、分娩前及产后24h血清VEGF及sFlt-1水平。结果三组GDM患者不同孕周VEGF水平均比同期对照组高(P<0.05);FGR组孕期及产后sFlt-1水平均比同期其余三组高(P<0.05);除巨大儿组外,其余三组孕期sFlt-1水平随孕周增加逐步升高(P<0.05)。结论 GDM患者孕中晚期VEGF水平变化平稳,总体水平高于正常妊娠者;GDM孕妇孕期sFlt-1水平的变化影响胎儿发育结局。     

Fetal weight and progression of diabetic retinopathy

OBJECTIVE: To test the hypothesis that progression of diabetic retinopathy in pregnancy is associated with reduced fetal growth and related neonatal morbidity. METHODS: Women with type 1 diabetes (n = 205) were enrolled before 14 weeks' gestation in a prospective study of diabetes in pregnancy and treated with intensive insulin therapy. They had serial ophthalmologic evaluations before 20 weeks' gestation and in late gestation or postpartum. Subjects were divided into two groups based on whether retinopathy progressed (progression group) or remained unchanged (no progression group). RESULTS: Retinopathy progressed in 59 of 205 women (29%) and was associated with advanced White classification (P =.001): three (5%) were class B, 14 (23%) class C, 24 (41%) class D, and 18 (30%) class F-RF. Reduced fetal growth was associated with progression of retinopathy. Mean birth weight was lower (P =.02), and more infants were small for gestational age (P =.02) and had low birth weights (P =.02) in the progression group. More large-for-gestational-age infants were noted in the no-progression group (P =.04). Birth weight percentile distributions showed a shift of the curve to the left in the progression group (P =.03). There were no differences in gestational age at delivery, macrosomia, preterm delivery, respiratory distress syndrome, neonatal hypoglycemia, or neonatal death. Small for gestational age was associated with chronic hypertension (odds ratio [OR] 6.4; 95% confidence interval [CI] 1.5, 27.9) and retinopathy progression (OR 4.7; 95% CI 1.2, 23.8). CONCLUSION: Development and progression of diabetic retinopathy during pregnancy were associated with reduced fetal growth manifested as increased rate of small-for-gestational-age and low-birth-weight infants.     

Use of insulin glargine during pregnancy: a case-control pilot study

OBJECTIVE: To determine whether the use of insulin glargine during pregnancy is associated with an increase in the incidence of fetal macrosomia or adverse neonatal outcome. DESIGN: A matched case-control study. SETTING: Women's Centre, John Radcliffe Hospital, Oxford, UK. SAMPLE: Sixty-four pregnant women treated with insulin during their pregnancies, 20 with type I diabetes and 44 with gestational diabetes. METHODS: Two groups of women were compared in matched pairs. A study group of 32 pregnant women with diabetes treated with insulin glargine during their pregnancy and a control group of 32 pregnant women treated with an intermediate-acting human insulin (isophane or insulin zinc suspension) and matched for weight at booking, height, gestation at delivery, parity, fetal sex, duration of insulin use in pregnancy and glycaemic control during the third trimester of pregnancy (glycosylated haemoglobin [HbA(1c)] concentration and mean blood glucose concentration). MAIN OUTCOME MEASURES: Birthweight, centile birthweight, the incidence of fetal macrosomia (birthweight > 90th percentile) and neonatal morbidity in the two study groups. RESULTS: There was no significant difference between the birthweight or centile birthweight of babies born to the women treated with insulin glargine during pregnancy and that of the babies born to those in the control group treated with intermediate-acting human insulin. The overall incidence of fetal macrosomia was 12/32 (37.5%) in the insulin glargine group and 13/32 (40.6%) in the control group. There was no significant difference in neonatal morbidity between the groups. CONCLUSIONS: The results of this pilot study indicate that insulin glargine treatment during pregnancy does not appear to be associated with increased fetal macrosomia or neonatal morbidity.     

Intrauterine asphyxia and long-term outcome in preterm fetuses

The long-term outcome of 108 infants born before the 33rd week of gestation was evaluated and correlated to a fetal heart tracing from the last 24 hours before delivery. Infants with signs of asphyxia (N = 30) were born at the same gestational age as those without (N = 78), but had a significantly lower birth weight (P less than .001). Severe intraventricular hemorrhage occurred more often in infants with asphyxia (30%) than in those without (5%) (P less than .05). Fourteen of 30 asphyxia infants (47%) and 11 of 78 nonasphyxia infants (14%) died within the first two years (P less than .005). At two years of age, four (25%) asphyxia and eight (12%) nonasphyxia infants have developmental or neurologic abnormalities (not significant). Of the eight infants with asphyxia born before the 29th week of gestation in the present study, none was normal at two years of age. The authors conclude that signs of asphyxia, as determined from fetal heart rate pattern, were associated with poor fetal outcome, and especially in infants born before the 29th week of gestation. The clinical implications of these findings are discussed.     

Macrosomia in the postdate pregnancy: is routine ultrasonographic screening indicated?

Macrosomia is a potential but often overlooked consequence of the postdate pregnancy. A total of 317 consecutive patients with well-dated pregnancies who were seen because of fetal surveillance at greater than 41 weeks' gestation had an estimation of the fetal weight based on femur length and abdominal circumference at the initial visit. The incidence of macrosomia at 41 weeks' gestation was 25.5%. There was a higher incidence of cesarean section because of arrest and protraction disorders in the postdate pregnancies in which the infant was macrosomic (22%) versus those in which the infant was not macrosomic (10%, p less than 0.01). In a control group of 100 consecutive women delivered between 38 and 40 weeks' gestation, the incidence of macrosomia was 4%, significantly lower than the rate in the postdate patients (p less than 0.01). Incidence of cesarean section because of arrest and protraction disorders was significantly lower in this group (6%, p less than 0.05). The sensitivity and specificity of an estimated fetal weight greater than 4000 gm to predict a birth weight greater than 4000 gm were 60.5% and 90.7%, respectively, with a positive predictive value of 70% and a negative predictive value of 87%. We conclude that routine ultrasonographic screening for macrosomia may be a valuable adjunct to current fetal surveillance protocols used in the postdate pregnancy.     

Value of ultrasonic fetometry for fetal monitoring in diabetes mellitus

Evaluation of ultrasonic fetometry in diabetic pregnancy. In 51 cases we have carried out 134 ultrasonic investigations. The diabetes we classified to the score of White A--F. To evaluate the increase in fetal weight and the maturity in a qualified sense, we measured the biparietal diameter, the transversal and the sagital diameter of the thorax and the trunk length. The findings were registered into diagrams of our percentiles of development.--The fetopathia diabetica will be diagnosed right, if it is joint with fetal hypertrophy. The beginning of the macrosomia of the fetus is possible to recognize from the 32th week of gestation.     

Patterns of alcohol consumption during pregnancy

Alcohol consumption among 530 pregnant women was recorded retrospectively from the last menstrual period to a mean of ten gestational weeks, and thereafter prospectively to term. Fifty-five percent of women had drunk alcohol (average 66 g of ethanol) during the week when ovulation was assumed to have taken place. This was not significantly different from the figures in 100 women seeking contraception, of whom 72% drank on average 61 g of ethanol during the ovulation week. Ninety percent of women drank alcohol at least once after the diagnosis of pregnancy. Drinking more than 600 g of ethanol during the first 12 gestational weeks (about four drinks weekly) was associated with an increased frequency of preterm delivery (P less than .05), but fetal outcome was not compromised. The proportion of drinking women decreased with advancing gestational age, with only 50% drinking after 32 weeks and only 20% during the last week of gestation. Beer was most commonly consumed, followed by wine and liquor. Alcohol consumption during pregnancy ranged between 7 and 4440 g, but 90% of the subjects drank less than 1100 g (zero to two drinks per week). Thus, women tended to decrease their drinking during pregnancy. Fewer than two drinks weekly had no detectable adverse effects on the fetal outcome.     

Umbilical and uteroplacental blood flow velocity waveforms in pregnancies with fetal growth retardation

A 2 MHZ pulsed Doppler ultrasound was used to record blood flow velocity waveforms (FVW) in the umbilical and arcuate arteries of 129 singleton pregnancies where intra-uterine growth retardation (IUGR) was suspected at routine ultrasound screening in the 32nd week of gestation. All patients were examined once a fortnight, between 32nd week and delivery, the results presented being from the final examination before delivery. The FVW were characterized by the pulsatility index (PI). Sixty-six of the 129 newborns were growth-retarded at delivery (birthweight less than or equal to mean--2SD of the general population). Of the IUGR cases, 56% had an abnormal PI (greater than or equal to mean + 2SD of normals) in the umbilical artery and 47% in the arcuate artery. Significant relationships were found between abnormal umbilical artery PI and both IUGR (p less than 0.001) and operative delivery for fetal distress (ODFD) (p less than 0.001). No such relationship was found between abnormal PI in the arcuate artery and either IUGR or ODFD. Four placenta waveform classes (PWC), reflecting the FVW on either side of the placenta, are presented and compared with the outcome of pregnancy. The data show the umbilical artery FVW to be a good predictor of IUGR and intra-uterine fetal distress, whereas the arcuate artery FVW appears to have low predictive value for the above conditions.     

Sonographically detectable changes in placental structures in pregnancy. 5. Statistical comparison of the frequency distribution of placental stages 0-3 in newborn infants in a pregnancy of less than 37 weeks duration

The analysis of sonographically provable changes of placental structures in 97 pregnant women (202 examination) shows in cases with a duration of pregnancy less than 37 gestational weeks that stage 0 could be found statistically significant more frequent until the 32nd week of pregnancy, stage 1 in the whole pregnancy, stage 2 and 3 between the 29. and 36. gestational week. Stage 0 and 1 don't effect prematurity; however stages 2 and 3 could be proved before the 32nd or 34th week of pregnancy in 41 or 100% of examination respectively and effect a premature birth. Stage 2 could be proved 2,8 times more frequent and stage 3 4 times more frequent in premature babies than in newborns with a normal duration of pregnancy.     

巨大儿孕妇孕期体重的动态分析

目的:探讨孕妇孕期增重及各孕期体重增加速度与分娩巨大儿的相关性,以冀开展有针对性的孕期管理,降低巨大儿的发生率。方法:回顾分析106例巨大儿和109例正常体重出生儿(对照组)母亲的孕前体重及孕期体重变化。结果:巨大儿组孕妇孕前体重,孕前BMI,孕期增重均高于对照组(P<0.01),两组孕妇体重增长速度最快时期均为孕20~30周,巨大儿组在孕20~30周及孕30周~分娩两期体重增速均高于对照组(P<0.01)。结论:巨大儿发生与孕妇孕前体重,孕前BMI,孕期增重等因素相关,应密切观察孕妇各孕期体重的变化,尤其是孕中晚期。     

Maternal obesity as a risk factor in gestational diabetes

Maternal obesity has been associated with both gestational diabetes mellitus (GDM) and neonatal macrosomia. Most studies of obesity in pregnancy have demonstrated an increased risk for GDM. However, the contribution of obesity as an added risk in GDM has not been examined. The purpose of this study was to examine the contribution of obesity as a risk factor to perinatal morbidity in gestationally diabetic women by comparing the maternal and neonatal outcome in obese and nonobese gestationally diabetic women. From 1979 to 1983, the maternal, intrapartum, and neonatal characteristics of all prepartum gravid patients with GDM were examined. Of the 158 patients with documented GDM, 62 (39%) were obese (weight greater than 90 kg). There was no difference in maternal age (obese 29.3 +/- 5.4 years, nonobese 28.7 +/- 6.5 years) parity, or prepartum risk score between the obese and nonobese patients. The incidence of prematurity, pre-eclampsia, fetal distress, and primary cesarean sections were not different between the groups. There were no differences in Apgar scores, gestational age, or perinatal morbidity. However, the obese patients delivered heavier neonates expressed as mean birthweight (obese 3667 +/- 682 gms, nonobese 3331 +/- 750 gms. P less than .01), the number of macrosomic (greater than 4 kg) neonates (obese 37%, nonobese 14%, P less than .001) and K-score, (obese 0.8 +/- 1, nonobese 0.4 +/- 9, P less than .05). These data indicate that obese patients with GDM have an increased risk of neonatal macrosomia.(ABSTRACT TRUNCATED AT 250 WORDS)     

The use of breast stimulation to prevent postdate pregnancy

Postdate pregnancy is estimated to occur in 3% to 12% of all gestations. Morbidity and mortality rates associated with this common obstetric problem are higher than those with term gestation. The incidence of fetal distress, birth injury, meconium aspiration, congenital malformations, macrosomia, and oligohydramnios is also greater in postdate pregnancy. We prospectively evaluated breast self-stimulation to determine its effect on the incidence of postdate pregnancy. Two hundred low-risk patients at 39 weeks' gestation were randomly assigned to either a control group or a breast stimulation group. Results showed that breast stimulation reduced the number of pregnancies managed as postdates from 17 per 100 (17%) to five per 100 (5%) (p < 0.01), a 70% reduction. It is concluded that breast stimulation in postdates pregnancies can decrease significantly the number of patients that must be monitored by biochemical or biophysical means.     

Influence of gestational age on prediction of fetal lung maturity by fluorescence polarization of amniotic fluid

Compared are the amniotic fluid fluorescence polarization values and the neonatal outcomes of 201 pregnant women who delivered from 28 through 37 weeks of gestation within 48 hours of the fluorescence polarization determinations. Thirty-five neonates developed hyaline membrane disease. The corresponding fluorescence polarization values ranged from 0.275 to 0.391. Eight of those 35 tests results were less than 0.325. The predictiveness of the method was studied using different threshold fluorescence polarization values. At the authors' own threshold of less than or equal to 0.325, the overall predictive value was as follows: false mature predictions: 6.2%, false immature predictions: 62.5%, sensitivity: 77.1%, and specificity: 72.8%. However, the false mature prediction rate was 21 to 40% from week 28 through week 33 versus 3.4 to 5.8% from week 34 through week 37, depending on the selected cutoff fluorescence polarization value. The sensitivity and specificity before, at, or after week 34 were significantly different at all tested fluorescence polarization values (P less than .05 to P less than .01) with the exception of the sensitivity at 0.310 and at 0.316 (P = .057). Caution is advised against relying on the fluorescence polarization method to predict fetal lung maturity at least before 34 weeks of gestation.